#USA #New York #Class Action #Rosen Law Firm #Skye Bioscience

Investors Alert: Skye Bioscience Class Action Lawsuit

The Rosen Law Firm, a renowned advocate for investor rights, is reaching out to individuals who purchased securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024, and October 3, 2025, to inform them about an important opportunity arising from a securities fraud lawsuit. With a critical deadline of January 16, 2026, approaching for those interested in becoming lead plaintiffs, this is a pivotal moment for investors to act and possibly reclaim their losses.

What You Need to Know

Purchasing Skye Bioscience securities during the specified period may entitle you to compensation. Importantly, this can be pursued without incurring upfront fees due to a contingency fee arrangement. The Rosen Law Firm has already initiated a class action lawsuit on behalf of affected investors who believe they have suffered losses due to the misleading statements made by the defendants regarding Skye's business operations and prospects.

The Allegations

The lawsuit asserts that throughout the designated class period, the defendants provided materially false and misleading information to investors, particularly regarding the efficacy of Skye’s drug, nimacimab. Specifically, it is alleged that:
1. The effectiveness of nimacimab was overstated.
2. Clinical and commercial prospects for the drug were inaccurately represented.
3. Public statements made by the defendants were misleading at all relevant times.

As a result of these claims, when the truth about nimacimab's performance came to light, investors faced significant financial damages. If you purchased stocks during this timeframe, your participation in this class action could be crucial in seeking redress.

How to Join the Class Action

If you wish to join the lawsuit, the process is straightforward:

• - Visit the Rosen Law Firm’s dedicated webpage on this case at rosenlegal.com.
• - For direct assistance, call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected].

It’s essential to note that till a class is certified, being a part of the lawsuit does not guarantee representation by counsel unless you actively decide to retain one. However, remaining as an absent class member does not preclude your ability to participate in any potential recovery.

Why Choose Rosen Law Firm?

Rosen Law Firm stands out for its extensive experience and successful track record in securities class actions, consistently recognized for its achievements in this complex legal field. In 2017, the firm achieved the largest securities class action settlement against a Chinese company and has ranked amongst the top firms annually, recovering hundreds of millions of dollars in settlements for investors.

Larry Rosen, the firm’s founder, was recently honored by Law360 as a Titan of Plaintiffs' Bar, further affirming the firm’s dedication to advocating for investor rights.

Given the intricacies of the securities landscape, selecting qualified counsel with tangible results is paramount. Many firms simply refer clients without actively litigating cases, leaving investors at risk of inadequate representation. By choosing Rosen Law Firm, you ensure that your interests are vigorously defended by seasoned professionals in securities litigation.

Conclusion

This is a critical juncture for investors in Skye Bioscience, Inc. If you have any inquiries about the class action lawsuit or your eligibility to participate, do not hesitate to reach out through the provided contact avenues. Taking action now may put you on the path to recovering your losses while also holding the responsible parties accountable for their misleading practices. Keep an eye on updates from the Rosen Law Firm to remain informed about the progress of this case and further developments regarding securities class actions.